Late stage investors in Cambridge, Massachusetts
Updated 16 Nov 2026
Venture funds
1 funds, by portfolio companies funded in the last 12 months| # | Fund | Sectors | Stages | Leads | Funded, 12 months |
|---|---|---|---|---|---|
| 1 | Founder Collective Founder Collective backs seed-stage startups, with recent investments including Baselayer, WHOOP and Ownwell. Cambridge, United States |
Artificial intelligence, Commerce | Seed, Early stage venture, Late stage venture | 6% | 2 |
Table 1. Late stage investors in Cambridge, Massachusetts: venture capital and micro VC funds ranked by companies whose Series C and later round closed in the last 12 months. Leads is the share of all recorded investments where the fund was lead investor. Source: FundingWatcher. Data as of 16 November 2026.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| Atlas Venture | Venture capital firm | Cambridge, United States | •••@atlasventure.com | 857 20••• |
| Founder Collective | Venture capital firm | Cambridge, United States | •••@foundercollective.com | (617) ••• |
| F-Prime | Venture capital firm | Cambridge, United States | •••@fprimecapital.com | |
| Accomplice | Family office | Cambridge, United States | •••@accomplice.co | 617-58••• |
| Sanofi Ventures | Corporate venture arm | Cambridge, United States | •••@gmail.com | +1 617••• |
| HealthCare Ventures | Venture capital firm | Cambridge, United States | •••@hcven.com | 617-25••• |
| Flint Capital | Venture capital firm | Cambridge, United States | •••@flintcap.com | |
| Mission BioCapital | Venture capital firm | Cambridge, United States | •••@missionbiocapital.com | +1 617••• |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
| Firm | Person | Title | Verified email | |
|---|---|---|---|---|
| Atlas Venture | B••• B••• | Partner | b•••@atlasventure.com | In the CSV |
| Founder Collective | A••• H••• | General Partner | a•••@foundercollective.com | In the CSV |
| F-Prime | S••• J••• | General Partner and Co-Founder, Investing in AI Native Software | s•••@fprimecapital.com | In the CSV |
| Accomplice | S••• A••• D••• | Operating Partner | s•••@accomplice.co | In the CSV |
| Flagship Pioneering | I••• M••• | General Partner | i•••@flagshippioneering.com | In the CSV |
5 verified partner contact rows from organizations on this list, names and emails masked.
- 30 of the 51 late stage investors in Cambridge, Massachusetts have a published email address, 28 a phone number and 46 a website.
- Atlas Venture has the most recorded investments, 638, 179 of them as lead investor.
- 10 of them are investors in at least one company that closed its most recent round in the last 12 months.
- Founder Collective is an investor in 5 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is T-Therapeutics' $133.0M Series B on 5 November 2026.
- Software is the most common sector across their 447 portfolio companies (73%).
- Early stage venture is the most common investment stage, recorded for 49 of them (96%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Late stage investors in Cambridge, Massachusetts
30 of 51, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Atlas Venture | Venture capital firm | Cambridge, United States | Health care, Biotech | Diagonal Therapeutics | 1 | 638 | 179 | 199 | •••@atlasventure.com | 857 20••• | In the CSV |
| 2 | Founder Collective | Venture capital firm | Cambridge, United States | Artificial intelligence, Commerce | Baselayer, WHOOP, Ownwell | 5 | 543 | 35 | 161 | •••@foundercollective.com | (617) ••• | In the CSV |
| 3 | F-Prime | Venture capital firm | Cambridge, United States | Health care, Fintech | T-Therapeutics, Albert Invent, Immuneel Therapeutics | 4 | 540 | 133 | 113 | •••@fprimecapital.com | In the CSV | |
| 4 | Accomplice | Family office, Venture capital firm | Cambridge, United States | Fintech, Artificial intelligence | Veera | 1 | 386 | 101 | 88 | •••@accomplice.co | 617-58••• | In the CSV |
| 5 | Flagship Pioneering | Venture capital firm | Cambridge, United States | Biotech, Health care | Inari, Prologue Medicines, Quotient Therapeutics | 288 | 104 | 72 | 617-86••• | In the CSV | ||
| 6 | SR One | Venture capital firm | Cambridge, United States | Biotech, Health care | Asceneuron | 214 | 69 | 69 | (610) ••• | In the CSV | ||
| 7 | CVP Management | Micro VC fund, Venture capital firm | Cambridge, United States | Hardware, Commerce | TimeTrade, Podium Data, FamilyID | 152 | 16 | 37 | In the CSV | |||
| 8 | Sanofi Ventures | Corporate venture arm | Cambridge, United States | Biotech, Health care | i2o Therapeutics, Tisento Therapeutics, NGI | 119 | 31 | 28 | •••@gmail.com | +1 617••• | In the CSV | |
| 9 | Johnson & Johnson Innovation | Corporate venture arm | Cambridge, United States | Health care, Biotech | ONL Therapeutics, Flindr Therapeutics, Asgard Therapeutics | 118 | 39 | 26 | In the CSV | |||
| 10 | HealthCare Ventures | Venture capital firm | Cambridge, United States | 109 | 22 | 36 | •••@hcven.com | 617-25••• | In the CSV | |||
| 11 | Flint Capital | Venture capital firm | Cambridge, United States | Artificial intelligence, Hardware | Bluebricks, Antidote Health, Nokod Security | 101 | 36 | 18 | •••@flintcap.com | In the CSV | ||
| 12 | Clarus Ventures | Venture capital firm | Cambridge, United States | Biotech, Health care | ESBATech | 88 | 38 | 34 | 888-75••• | In the CSV | ||
| 13 | Mission BioCapital | Venture capital firm | Cambridge, United States | Biotech, Health care | Circle Pharma, Cloverleaf Bio, Integrated Biosciences | 4 | 85 | 17 | 19 | •••@missionbiocapital.com | +1 617••• | In the CSV |
| 14 | Safar Partners | Private equity firm, Venture capital firm | Cambridge, United States | Biotech, Health care | Gelmedix | 1 | 85 | 17 | 7 | •••@safar.partners | (646) ••• | In the CSV |
| 15 | Romulus Capital | Venture capital firm | Cambridge, United States | Health care, Fintech | Albiware, Lora DiCarlo, Placester | 71 | 34 | 15 | •••@romuluscap.com | +1 888••• | In the CSV | |
| 16 | Link Ventures | Venture capital firm | Cambridge, United States | Commerce, Fintech | Enlaye, Blitzy, Dono | 3 | 71 | 27 | 6 | •••@linkventures.com | In the CSV | |
| 17 | Fairhaven Capital Partners | Venture capital firm | Cambridge, United States | Hardware, Cybersecurity | Pwnie Express, Py, ShopWell | 71 | 20 | 24 | •••@fairhavencapital.com | (617) ••• | In the CSV | |
| 18 | HubSpot Ventures | Corporate venture arm | Cambridge, United States | Artificial intelligence, Commerce | Agency AI, Artisan AI, doola | 64 | 12 | 8 | •••@hubspot.com | +1 888••• | In the CSV | |
| 19 | Koa Labs | Venture capital firm | Cambridge, United States | Artificial intelligence, Health care | OncoveryCare, Hopara, AskFora | 50 | 0 | 6 | •••@koalab.com | +1 603••• | In the CSV | |
| 20 | Rhapsody Venture Partners | Venture capital firm | Cambridge, United States | Hardware, Artificial intelligence | Polaris Electro-Optics | 1 | 46 | 25 | 2 | •••@rhapsodyvp.com | In the CSV | |
| 21 | SpringTide Ventures | Venture capital firm | Cambridge, United States | Health care, Artificial intelligence | Prolucent Health, Leash Biosciences, Binkey | 43 | 12 | 6 | 801-82••• | In the CSV | ||
| 22 | Tectonic Ventures | Venture capital firm | Cambridge, United States | Artificial intelligence, Hardware | Marveri, Humatics, OmniML | 43 | 3 | 4 | In the CSV | |||
| 23 | Waterline Ventures | Venture capital firm | Cambridge, United States | Health care, Artificial intelligence | Manifold | 1 | 41 | 10 | 8 | •••@waterlineventures.com | (857) ••• | In the CSV |
| 24 | Causeway Media Partners | Private equity firm, Venture capital firm | Cambridge, United States | Commerce | Freeletics, SquadLocker, SportsEngine | 34 | 12 | 9 | •••@causewaymp.com | 617.85••• | In the CSV | |
| 25 | Biogen | Venture capital firm | Cambridge, United States | Biotech, Health care | Autobahn Therapeutics | 32 | 9 | 19 | +1 781••• | In the CSV | ||
| 26 | Action Potential Venture Capital | Venture capital firm | Cambridge, United States | Health care | Presidio Medical | 30 | 5 | 3 | (888) ••• | In the CSV | ||
| 27 | LSP BioVentures | Venture capital firm | Cambridge, United States | Biotech, Health care | Innovative Molecules, Luxendo, Affectis Pharmaceuticals | 29 | 14 | 18 | •••@yfcip.pbz | (781) ••• | In the CSV | |
| 28 | Rivas Capital | Venture capital firm | Cambridge, United States | Artificial intelligence, Biotech | ReviveMed, Comgy | 25 | 5 | 5 | (857) ••• | In the CSV | ||
| 29 | Remiges Ventures | Venture capital firm | Cambridge, United States | Biotech, Health care | Kupando | 1 | 24 | 15 | 0 | |||
| 30 | Yonjin Venture | Venture capital firm | Cambridge, United States | 24 | 5 | 7 | •••@yjventure.com | (657) ••• |
Table 2. Late stage investors in Cambridge, Massachusetts: the first 30 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 51.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | Founder Collective | Cambridge, United States | 5 | 119 | Baselayer, WHOOP, Ownwell |
| 2 | F-Prime | Cambridge, United States | 4 | 75 | T-Therapeutics, Albert Invent, Immuneel Therapeutics |
| 3 | Mission BioCapital | Cambridge, United States | 4 | 8 | Circle Pharma, Cloverleaf Bio, Integrated Biosciences |
| 4 | Link Ventures | Cambridge, United States | 3 | 14 | Enlaye, Blitzy, Dono |
| 5 | Rhapsody Venture Partners | Cambridge, United States | 1 | 3 | Polaris Electro-Optics |
| 6 | Remiges Ventures | Cambridge, United States | 1 | 3 | Kupando |
| 7 | Safar Partners | Cambridge, United States | 1 | 4 | Gelmedix |
| 8 | Accomplice | Cambridge, United States | 1 | 47 | Veera |
| 9 | Atlas Venture | Cambridge, United States | 1 | 47 | Diagonal Therapeutics |
| 10 | Waterline Ventures | Cambridge, United States | 1 | 4 | Manifold |
Table 3. Late stage investors in Cambridge, Massachusetts: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime | 51 to 100 | 2022 |
| Albert Invent | Albert Invent builds an AI platform that supports chemistry research and development for scientific and industrial users. | Artificial intelligence | Oakland, United States | Series B | $55.0M | 2026-10-13 | $105.0M | F-Prime | 101 to 250 | 2022 |
| Baselayer | Baselayer automates risk assessment and fraud detection for financial and government institutions. | Artificial intelligence | New York, United States | Series A | $35.0M | 2026-09-22 | $82.0M | Founder Collective | 51 to 100 | 2024 |
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco, United States | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital | 11 to 50 | 2012 |
| Polaris Electro-Optics | Polaris Electro-Optics develops integrated photonics for communications and computation. | Hardware | Broomfield, United States | Series B | $50.0M | 2026-09-15 | $63.2M | Rhapsody Venture Partners | 11 to 50 | 2021 |
| Cloverleaf Bio | Cloverleaf Bio develops an RNA therapeutic platform for oncology. | Biotech | New Haven, United States | Seed | $33.0M | 2026-09-08 | $33.0M | Mission BioCapital | 1 to 10 | 2023 |
| Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City, United States | Series A | $68.4M | 2026-08-05 | $85.6M | Mission BioCapital | 11 to 50 | 2022 |
| Enlaye | Enlaye provides a cloud-based platform for writing, negotiating, and collaborating on contracts. | Artificial intelligence | Boston, United States | Seed | $5.0M | 2026-06-10 | $6.7M | Link Ventures | 1 to 10 | 2023 |
| Immuneel Therapeutics | Immuneel Therapeutics develops cell and gene therapies to treat cancer. | Health care | Bangalore, India | Series B | $10.5M | 2026-06-08 | $37.6M | F-Prime | 51 to 100 | 2018 |
| Blitzy | Blitzy automates custom software development using generative AI technology. | Artificial intelligence | Boston, United States | Series A | $200.0M | 2026-05-05 | $210.4M | Link Ventures | 101 to 250 | 2023 |
Table 4. Late stage investors in Cambridge, Massachusetts: the 10 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Software | 328 | 73% |
| Health care | 99 | 22% |
| Artificial intelligence | 74 | 17% |
| Fintech | 61 | 14% |
| Hardware | 60 | 13% |
| Biotech | 57 | 13% |
| Commerce | 43 | 10% |
| Cybersecurity | 35 | 8% |
| Education | 19 | 4% |
| Energy | 1 | 0% |
Table 5. Late stage investors in Cambridge, Massachusetts: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Late stage investors | 51 | 100% |
| Early stage investors | 49 | 96% |
| Seed investors | 35 | 69% |
| Venture investors | 23 | 45% |
| Private equity investors | 11 | 22% |
| Convertible note investors | 9 | 18% |
| Post IPO investors | 8 | 16% |
| Debt investors | 6 | 12% |
Table 6. Late stage investors in Cambridge, Massachusetts by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2020s | 4 | 9% |
| 2010s | 18 | 40% |
| 2000s | 12 | 27% |
| 1990s | 2 | 4% |
| 1980s | 5 | 11% |
| 1970s | 2 | 4% |
Table 7. Late stage investors in Cambridge, Massachusetts by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when its recorded investment stages include late stage investors and its headquarters is in Cambridge, Massachusetts. On 16 November 2026 that is 51 investors.
- 30 rows carry an email address and 28 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 30 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 51 rows: 5 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many late stage investors in Cambridge, Massachusetts are on the list?
- 51, in the file dated 16 November 2026. 10 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 30 of the 51 carry an email address in the download and 28 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 51 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 51 rows, 30 firm email addresses and 28 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 22 of the 30 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.